Septerna (SEPN) Current Deferred Revenue (2025 - 2026)
Septerna's (SEPN) quarterly Current Deferred Revenue came in at $59.8 million in Q1 2026, down 4.02% quarter-over-quarter from $62.3 million in Q4 2025.
Septerna (SEPN) Current Deferred Revenue (2025 - 2026) Analysis & Trends
Septerna's Current Deferred Revenue history runs 2 years deep, the most recent figure standing at $59.8 million for Q1 2026.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $59.8 million in Q1 2026; TTM through Mar 2026 was $59.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $62.3 million, changed N/A from the prior year.
- Current Deferred Revenue fell to $59.8 million in Q1 2026 per SEPN's latest filing, from $62.3 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $62.3 million in Q4 2025 and bottomed at $59.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Septerna | 1.50 Bn | 1.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.76 Mn |
| Dec 31, 2025 | 62.27 Mn |
| Sep 30, 2025 | 61.60 Mn |